FGFR4 Antikörper (AA 25-182)

Produktnummer ABIN7152841

Produktdetails anti-FGFR4 Antikörper

Target: FGFR4 (Fibroblast Growth Factor Receptor 4 (FGFR4))

Bindungsspezifität: AA 25-182

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser FGFR4 Antikörper ist unkonjugiert

Applikation: ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Fibroblast growth factor receptor 4 protein (25-182AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu FGFR4

Target: FGFR4 (Fibroblast Growth Factor Receptor 4 (FGFR4))

Andere Bezeichnung: FGFR4 (FGFR4 Produkte)

Synonyme: FGFR4 antikoerper, XFGFR-4 antikoerper, XFGFR-4a antikoerper, cd334 antikoerper, fgfr-4 antikoerper, jtk2 antikoerper, tkf antikoerper, xfgfr4 antikoerper, CD334 antikoerper, JTK2 antikoerper, TKF antikoerper, Fgfr-4 antikoerper, etID309818.21 antikoerper, wu:fc13h10 antikoerper, zgc:111935 antikoerper, fgfr-4c antikoerper, fgfr4 antikoerper, fibroblast growth factor receptor 4 antikoerper, fibroblast growth factor receptor 4 S homeolog antikoerper, FGFR4 antikoerper, fgfr4 antikoerper, Fgfr4 antikoerper, fgfr4.S antikoerper

Hintergrund:

Background: Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation, MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling.

Aliases: CD 334 antibody, CD334 antibody, CD334 antigen antibody, fc13h 10 antibody, fc13h10 antibody, Fgfr 4 antibody, FGFR-4 antibody, Fgfr4 antibody, FGFR4_HUMAN antibody, Fibroblast growth factor receptor 4 antibody, Hydroxyaryl protein kinase antibody, JTK 2 antibody, JTK2 antibody, MGC20292 antibody, Protein tyrosine kinase antibody, TKF antibody, Tyrosine kinase related to fibroblast growth factor receptor antibody, Tyrosylprotein kinase antibody

UniProt: P22455

Pathways: RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Carbohydrate Homeostasis, Growth Factor Binding